The Methodist Hospital System. Leading Medicine
The Methodist Hospital System. Leading Medicine

Methodist Breast Center

For Patients - Breast Medical Oncology Clinical Trials

  1. Protocol Title: A randomized phase II study to evaluate the combination of ixabepilone plus capecitabine or docetaxel plus capecitabine in the treatment of metastatic breast cancer (IRB #1107-0225)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 441-5785

    - This study includes patients > 18 years of age, with metastatic breast cancer (first and second line of treatment). Measurable disease with HER2-positive subjects will be allowed if they have progressed after receiving treatment with trastuzumab or lapatinib. Subjects may be enrolled with triple-negative (TN) disease (not expressing ER, PR, or HER2/neu) or non-triple-negative (NTN) disease.

  2. Protocol Title: Exploratory analysis of protein expression profiles in nipple aspiration fluid of breast cancer patients (IRB# 1107-0227)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 441-5785

    - Patients who are candidate for neoadjuvant chemotherapy, disease stage (T1N1-3M0 to T2-4 N0-3M0).

  3. Protocol Title: Exploratory analysis of protein expression profiles in nipple aspiration fluid of patients with abnormal mammographic findings (IRB#1107-0234)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 441-5785

    - Patients without a personal history of breast cancer but with recent abnormal or suspicious mammographic findings.

  4. Protocol Title: breast medical oncology section tissue and serum bank project (IRB# 0208-0033)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 441-6011

    - The Breast Medical Oncology tissue and serum bank is expected to be utilized in a wide variety of research projects that may improve upon existing knowledge regarding the pathology, genetics, and treatment of breast cancer patients.

  5. Protocol Title: A multicenter, screening study of patients with breast cancer for urine PGE-M levels and cyclooxygenase 2 expression in tumor samples (IRB# 0508-0067)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 441-6011

    - Patients who are ≥ 18 years of age with either metastatic or early stage breast cancer with intact tumor and Her2/neu positive (any ER/PR), ER+ and/or PR+, Her2 negative, triple negative breast cancer (ER/PR/Her2 negative), or those patients who have been recently diagnosed with breast cancer and have had surgery and are currently tumor-free.

  6. Protocol Title: A randomized, double blind, placebo controlled, multicenter, phase II study of the safety and efficacy of apricoxib in combination with lapatinib and capecitabine in the treatment of patients with HER2/neu positive breast cancer who have failed trastuzumab and chemotheraphy including a taxane (IRB# 0308-0046)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 441-6011

    - This study includes patients with pathologically determined locally advanced or metastatic (HER2/neu+) breast cancer. Their HER2/neu status should be positive. They should have progressed after treatment with chemotherapy including a taxane and trastuzumab. They should be ≥ 18 years of age.

  7. Protocol Title: Weight gain prevention for breast cancer survivors (IRB # 0508-0084)
    Principal Investigator: Edgardo Rivera, M.D.
    Phone Number: (713) 563-3751

    - This study evaluates the effect of a weight gain prevention program, compared to usual care, on weight, body composition, and biomarkers related to breast cancer prognosis. It will explore whether changes in physical activity, energy intake, and resting energy expenditure predict weight gain among breast cancer survivors.